Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Metastatic cancers cause over 90% of cancer mortality, driven by extracellular matrix-degrading enzymes.
• Matrix metalloproteinases (MMPs) are key enzymes in cancer metastasis, with their activity often dysregulated in aggressive tumors.
• Tetracyclines, particularly chemically modified non-antibiotic tetracyclines (CMTs), exhibit MMP inhibitory properties and are explored for anticancer potential.

Purpose of the Study:

• To evaluate the anticancer efficacy of chemically modified non-antibiotic tetracyclines (CMTs), specifically CMT-3 and CMT-308, against various cancer types.
• To investigate the mechanisms underlying the anti-metastatic and anti-proliferative effects of CMTs.
• To compare the potency of CMTs with traditional tetracyclines like doxycycline and minocycline.

Main Methods:

• CMTs were tested in prostate, breast, and melanoma tumor models.
• In vitro and in vivo assays were used to assess MMP inhibition, cell proliferation, apoptosis, and tumor growth.
• Mechanisms of action, including hydroxyl free radical generation, mitochondrial depolarization, and effects on angiogenesis, were analyzed.

Main Results:

• CMT-3 and CMT-308 significantly inhibited cancer cell invasion, MMP activity, proliferation, and induced apoptosis.
• CMTs were more potent than doxycycline and minocycline in inhibiting tumor cell-derived MMPs and inducing apoptosis.
• CMT-3 demonstrated significant inhibition of tumor growth in xenografts and bone metastasis models, with observed reductions in angiogenesis and increased apoptosis.

Conclusions:

• CMTs, particularly CMT-3, possess potent anticancer properties by targeting MMPs and inducing apoptosis through hydroxyl free radical generation.
• CMT-3 exhibits significant therapeutic potential in preclinical models of prostate, melanoma, and breast cancers.
• The promising preclinical results of CMT-3 have led to its investigation in human clinical trials for various cancers.